Wolf K. Hofmann
Department of Hematology and Oncology
Johann Wolfgang Goethe University Hospital
Frankfurt/Main
Germany
Name/email consistency: high
- Myelodysplastic syndromes. Hofmann, W.K., Lübbert, M., Hoelzer, D., Phillip Koeffler, H. Hematol. J. (2004)
- Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann, W.K., Heil, G., Zander, C., Wiebe, S., Ottmann, O.G., Bergmann, L., Hoeffken, K., Fischer, J.T., Knuth, A., Kolbe, K., Schmoll, H.J., Langer, W., Westerhausen, M., Koelbel, C.B., Hoelzer, D., Ganser, A. Ann. Hematol. (2004)
- Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Hofmann, W.K., Komor, M., Hoelzer, D., Ottmann, O.G. Leuk. Lymphoma (2004)
- Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Hofmann, W.K., Komor, M., Wassmann, B., Jones, L.C., Gschaidmeier, H., Hoelzer, D., Koeffler, H.P., Ottmann, O.G. Blood (2003)
- Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Hofmann, W.K., Jones, L.C., Lemp, N.A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O.G., Koeffler, H.P. Blood (2002)
- Loss of genomic imprinting of insulin-like growth factor 2 is strongly associated with cellular proliferation in normal hematopoietic cells. Hofmann, W.K., Takeuchi, S., Frantzen, M.A., Hoelzer, D., Koeffler, H.P. Exp. Hematol. (2002)
- Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Hofmann, W.K., de Vos, S., Komor, M., Hoelzer, D., Wachsman, W., Koeffler, H.P. Blood (2002)
- Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Hofmann, W.K., Seipelt, G., Langenhan, S., Reutzel, R., Schott, D., Schoeffski, O., Illiger, H.J., Hartmann, F., Balleisen, L., Franke, A., Fiedler, F., Huber, C., Rasche, H., Bergmann, L., Ganser, A., Pott, C., Pasold, R., Rudolph, C., Ottmann, O.G., Gökbuget, N., Hoelzer, D. Ann. Hematol. (2002)
- Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Hofmann, W.K., Miller, C.W., Tsukasaki, K., Tavor, S., Ikezoe, T., Hoelzer, D., Takeuchi, S., Koeffler, H.P. Leuk. Res. (2001)
- Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Hofmann, W.K., de Vos, S., Tsukasaki, K., Wachsman, W., Pinkus, G.S., Said, J.W., Koeffler, H.P. Blood (2001)
- Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes. Hofmann, W.K., Takeuchi, S., Xie, D., Miller, C.W., Hoelzer, D., Koeffler, H.P. Leuk. Res. (2001)
- Defective megakaryocytic development in myelodysplastic syndromes. Hofmann, W.K., Kalina, U., Koschmieder, S., Seipelt, G., Hoelzer, D., Ottmann, O.G. Leuk. Lymphoma (2000)
- Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels. Hofmann, W.K., Seipelt, G., Ottmann, O.G., Kalina, U., Koschmieder, S., Brücher, J., Frickhofen, N., Klausmann, M., Mitrou, P.S., Hoelzer, D. Ann. Hematol. (2000)
- Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Hofmann, W.K., Ganser, A., Seipelt, G., Ottmann, O.G., Zander, C., Geissler, G., Hoffmann, K., Höffken, K., Fischer, J.T., Isele, G., Hoelzer, D. Ann. Hematol. (1999)
- Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha. Hofmann, W.K., Kalina, U., Seipelt, G., Hoffmann, K., Wagner, S., Hoelzer, D., Ottmann, O.G. Eur. J. Haematol. (1999)
